Additionally, a range of peptide DPP4 inhibitors have been confirmed to reduce colitis in mice through the same pathway (Salaga et al., 2017, 2018), indicating that the overexpression of intestinal DPP4 is closely related to IBD. This evidence concerns the gene DPP4 and inflammatory bowel disease.